The CRISPR market had an estimated market share worth US$ 3.4 billion in 2023, and it is predicted to reach a global market valuation of US$ 17.8 billion by 2034, growing at a CAGR of 16.1% from 2024 to 2034.
The market for CRISPR is primarily driven by the rising need for targeted medical treatments, the growth of biotechnology and agricultural applications, and improvements in delivery methods.
Collaborations among stakeholders, as well as advances in safety and effectiveness profiles, drive market expansion and acceptance across a wide range of industries.
Demand Analysis of CRISPR
| Report Attribute | Details |
|---|---|
| Estimated Market Value in 2023 | US$ 3.4 billion |
| Expected Market Value in 2024 | US$ 4 billion |
| Projected Forecast Value in 2034 | US$ 17.8 billion |
| Anticipated Growth Rate from 2024 to 2034 | 16.1% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for the CRISPR market was estimated to reach a valuation of US$ 1.7 billion in 2019, according to a report from Future Market Insights (FMI). From 2019 to 2023, the CRISPR market witnesses significant growth, registering a CAGR of 18.9%.
| Historical CAGR from 2019 to 2023 | 18.9% |
|---|---|
| Forecast CAGR from 2024 to 2034 | 16.1% |
The ground-breaking gene editing technology CRISPR-X was announced by researchers in 2023. CRISPR-X makes it possible to precisely target many genes at once. It provides exceptional precision with few off-target impacts.
This breakthrough might have revolutionary effects on clinical applications and genetic studies during the forecast period. Some important factors that will boost the market growth through 2034 are:
The market is expanding due to the growing need for CRISPR based treatments to address unmet medical needs, particularly in cancer and rare genetic diseases. The accuracy and adaptability of CRISPR provide exciting opportunities for the development of tailored therapies for diseases that were previously incurable.
With growing awareness of genetic illnesses and advances in genome editing technology, stakeholders are stepping up efforts to bring CRISPR medicines to market. This is anticipated to push research funding, clinical trials, and regulatory clearances to address the urgent patient needs globally.
Another key driver of the CRISPR industry is the growing use of gene editing technologies beyond healthcare, notably in agriculture as well as biotechnology. CRISPR provides accurate and effective tools for bioengineering, livestock breeding, and agricultural enhancement. Improving sustainability, food security, and industrial processes is under growing strain as the global population rises and environmental problems endure.
This encourages funding for CRISPR research and commercialization, creating opportunities for development and innovation in a variety of industries besides the healthcare industry.
Principal Consultant
Regulatory Obstacles and Ethical Issues to Impede the Market Growth
Regulatory obstacles, ethical issues, and intellectual property conflicts all impede market expansion for CRISPR technology. Research and commercialization efforts are limited by uncertain regulatory frameworks and growing ethical issues regarding gene editing.
Continuous disagreements about patent rights and license terms impede innovation and cooperation by causing ambiguity. Unlocking the full potential of CRISPR technology and promoting sustainable market growth require addressing these obstacles with clear rules, moral standards, and equitable dispute resolution procedures.
This section focuses on providing detailed analysis of two particular market segments for CRISPR, the top products and services and the dominant application. The two main segments discussed below are CRISPR kits & enzymes and drug discovery and development.
| Products and Services | CRISPR kits & Enzymes |
|---|---|
| CAGR from 2024 to 2034 | 15.8% |
During the forecast period, the CRISPR kits & enzymes segment is likely to garner a 15.8% CAGR. The need for CRISPR kits and enzymes is expected to rise as a result of growing research projects in a number of industries, including biotechnology, agriculture, and healthcare. These kits make gene editing experiments more accessible to scientists, encouraging research and experimentation.
Personalized medicine and agricultural enhancement are also gaining popularity, which increases the demand for effective gene editing techniques. The demand for CRISPR kits and enzymes is expected to soar in the global market to enable a wide range of applications and developments.
| Application Type | Drug Discovery & Development |
|---|---|
| Market Share in 2024 | 51.2% |
In 2024, the drug discovery & development segment is likely to acquire a 51.2% global market share. CRISPR is critical in drug discovery and development due to its capacity to precisely modify disease-related genes, allowing for faster target selection and confirmation.
CRISPR speeds up the drug development process by making it easier to create disease models for drug screening through effective genome editing.
CRISPR opens up new possibilities for customized therapy by potentially fixing mutations that cause illness in patient cells. CRISPR, thus, becomes a game-changing tool for redefining medication development approaches for a range of illnesses.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
This section will go into detail on the CRISPR markets in a few key countries, including the United States, the United Kingdom, China, Japan, and South Korea. This part will focus on the primary factors that are driving up demand in these countries for CRISPR.
| Country | CAGR |
|---|---|
| The United States | 16.3% |
| The United Kingdom | 16.9% |
| China | 16.5% |
| Japan | 17.2% |
| South Korea | 17.6% |
The United States CRISPR ecosystem is anticipated to gain a CAGR of 16.3% through 2034. Demand for CRISPR-based medicines is driven by rising investment in genetic therapies and precision medicine, which promotes improvements in illness management and individualized healthcare.
Growing concerns about food security and sustainability drive demand for CRISPR-enabled crop enhancements that boost yields, nutrient density, and disease resistance in agricultural goods.
The market in the United Kingdom is expected to expand with a 16.9% CAGR through 2034. Reputable academic and scientific organizations in the United Kingdom encourage CRISPR technology innovation, drawing talent and funding for ground-breaking developments in gene editing research and applications.
The advanced regulatory environment in the United Kingdom facilitates the ethical and appropriate application of CRISPR technology. It offers direction and clarity for research and commercialization endeavors, hence stimulating industry development and investment.
The CRISPR ecosystem in China is anticipated to develop with a 16.5% CAGR from 2024 to 2034. Significant government support and funding for biotechnology research and innovation, particularly CRISPR technology, drives progress and positions the country as a global leader in the industry.
The need for CRISPR-based treatments is fueled by China's emphasis on tackling health issues like cancer and genetic disorders, which has resulted in large investments and advancements in the field.
The CRISPR industry in Japan is anticipated to reach a 17.2% CAGR from 2024 to 2034. CRISPR-based medicines for customized medicine and targeted treatments are becoming more popular in Japan due to its focus on healthcare innovation and tackling common ailments like cancer and genetic abnormalities.
The regulatory landscape in Japan is favorable for novel medical technologies, which makes it easier to develop and market CRISPR-based therapies. This promotes investment and industry expansion.
The CRISPR ecosystem in South Korea is likely to evolve with a 17.6% CAGR during the forecast period. South Korea is at the forefront of stem cell research, and using CRISPR technology improves the accuracy and efficiency of gene editing in stem cells, increasing regenerative medicine as well as therapeutic applications.
The need for CRISPR technology is boosted by the strategic focus of the South Korean government on developing the biotech sector, which propels research and development and commercialization activities in the nation's booming biotech industry.
Significant players in the global CRISPR market, such as Editas Medicine, Intellia Therapeutics, and CRISPR Therapeutics, are fostering competition and innovation. These companies are actively working to improve the safety and effectiveness characteristics of CRISPR-based treatments for a range of genetic illnesses and diseases.
By conducting basic research and working with business partners, research institutes and academic centers also significantly contribute to the advancement of CRISPR technology.
Authorities like the FDA and EMA are keeping a careful eye on advances to make sure they are used safely and ethically. Key companies in the dynamic CRISPR market are characterized by their pursuit of rigorous research, strategic alliances, and regulatory compliance. The key players in this market include:
Significant advancements in the CRISPR market are being made by key market participants, and these include:
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 16.1% from 2024 to 2034 |
| Market Value in 2024 | US$ 4 billion |
| Market Value in 2034 | US$ 17.8 billion |
| Base Year for Estimation | 2023 |
| Historical Data | 2019 to 2023 |
| Forecast Period | 2024 to 2034 |
| Quantitative Units | US$ billion for value |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Countries Profiled |
|
| Key Companies Profiled |
|
| Customization Scope | Available on Request |
The CRISPR market is expected to garner a 16.1% CAGR from 2024 to 2034.
By 2024, the global CRISPR market is likely to gain US$ 4 billion.
By 2034, the CRISPR market valuation is likely to reach a sum of US$ 17.8 billion.
The CRISPR industry in the United States is likely to garner a 16.3% CAGR during the forecast period.
The CRISPR kits & enzymes will gain immense popularity and develop with a 15.8% CAGR through 2034.
The drug discovery & development segment by application type is likely to garner a 15.7% CAGR through 2034.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034 4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023 4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product & Services 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product & Services, 2019 to 2023 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product & Services, 2024 to 2034 5.3.1. Products 5.3.1.1. kits & Enzymes 5.3.1.2. Libraries 5.3.1.3. Other Products 5.3.2. Services 5.3.2.1. gRNA Design & Vector Construction 5.3.2.2. Cell Line Engineering 5.3.2.3. Screening Services 5.3.2.4. Other Services 5.4. Y-o-Y Growth Trend Analysis By Product & Services, 2019 to 2023 5.5. Absolute $ Opportunity Analysis By Product & Services, 2024 to 2034 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Application, 2019 to 2023 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Application, 2024 to 2034 6.3.1. Drug discovery & development 6.3.2. Agriculture 6.3.3. Other 6.4. Y-o-Y Growth Trend Analysis By Application, 2019 to 2023 6.5. Absolute $ Opportunity Analysis By Application, 2024 to 2034 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2019 to 2023 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2024 to 2034 7.3.1. Pharmaceutical & biotechnology companies 7.3.2. Academic & research institutes 7.3.3. Others 7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023 7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Product & Services 9.2.3. By Application 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product & Services 9.3.3. By Application 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Product & Services 10.2.3. By Application 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product & Services 10.3.3. By Application 10.3.4. By End User 10.4. Key Takeaways 11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Product & Services 11.2.3. By Application 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product & Services 11.3.3. By Application 11.3.4. By End User 11.4. Key Takeaways 12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Product & Services 12.2.3. By Application 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product & Services 12.3.3. By Application 12.3.4. By End User 12.4. Key Takeaways 13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Product & Services 13.2.3. By Application 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product & Services 13.3.3. By Application 13.3.4. By End User 13.4. Key Takeaways 14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Product & Services 14.2.3. By Application 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product & Services 14.3.3. By Application 14.3.4. By End User 14.4. Key Takeaways 15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Product & Services 15.2.3. By Application 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Product & Services 15.3.3. By Application 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2023 16.1.2.1. By Product & Services 16.1.2.2. By Application 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2023 16.2.2.1. By Product & Services 16.2.2.2. By Application 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2023 16.3.2.1. By Product & Services 16.3.2.2. By Application 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2023 16.4.2.1. By Product & Services 16.4.2.2. By Application 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2023 16.5.2.1. By Product & Services 16.5.2.2. By Application 16.5.2.3. By End User 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2023 16.6.2.1. By Product & Services 16.6.2.2. By Application 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2023 16.7.2.1. By Product & Services 16.7.2.2. By Application 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2023 16.8.2.1. By Product & Services 16.8.2.2. By Application 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2023 16.9.2.1. By Product & Services 16.9.2.2. By Application 16.9.2.3. By End User 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2023 16.10.2.1. By Product & Services 16.10.2.2. By Application 16.10.2.3. By End User 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2023 16.11.2.1. By Product & Services 16.11.2.2. By Application 16.11.2.3. By End User 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2023 16.12.2.1. By Product & Services 16.12.2.2. By Application 16.12.2.3. By End User 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2023 16.13.2.1. By Product & Services 16.13.2.2. By Application 16.13.2.3. By End User 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2023 16.14.2.1. By Product & Services 16.14.2.2. By Application 16.14.2.3. By End User 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2023 16.15.2.1. By Product & Services 16.15.2.2. By Application 16.15.2.3. By End User 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2023 16.16.2.1. By Product & Services 16.16.2.2. By Application 16.16.2.3. By End User 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2023 16.17.2.1. By Product & Services 16.17.2.2. By Application 16.17.2.3. By End User 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2023 16.18.2.1. By Product & Services 16.18.2.2. By Application 16.18.2.3. By End User 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2023 16.19.2.1. By Product & Services 16.19.2.2. By Application 16.19.2.3. By End User 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2023 16.20.2.1. By Product & Services 16.20.2.2. By Application 16.20.2.3. By End User 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2023 16.21.2.1. By Product & Services 16.21.2.2. By Application 16.21.2.3. By End User 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2023 16.22.2.1. By Product & Services 16.22.2.2. By Application 16.22.2.3. By End User 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2023 16.23.2.1. By Product & Services 16.23.2.2. By Application 16.23.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Product & Services 17.3.3. By Application 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Thermo Fisher Scientific, Inc 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Merck KGaA 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Agilent Technologies, Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Genscript Biotech Corporation 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Therapeutics AG 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Editas Medicine 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Intellia Therapeutics Inc 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Beam Therapeutics Inc 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Caribou Biosciences, Inc 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Lonza Group, Ltd. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
CRISPR Market
